Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

Autor: Erik J van Helden, Otto S Hoekstra, Ronald Boellaard, Chantal Roth, Emma R Mulder, Henk M W Verheul, C Willemien Menke-van der Houven van Oordt

Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0155178 (2016)

OBJECTIVE:The aim of this pilot study was to explore intrapatient mixed metabolic response and early 18F-FDG PET response evaluation using predefined quantification strategies in patients with advanced KRAS wild-type colorectal adenocarcinoma (mCRC)

Externí odkaz: https://doaj.org/article/49091125a27f4fd896e56f6e516d9af6

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Autor: Erik J van Helden, Sjoerd G. Elias, Henk M.W. Verheul, Elisabeth G.E. de Vries, Suzanne C van Es, Astrid Aplonia Maria Van Der Veldt, Sarah R. Verhoeff, Erik H.J.G. Aarntzen, Sjoukje F. Oosting, Winette T. A. van der Graaf, Sandra Heskamp, Otto S. Hoekstra, Otto C. Boerman, Lindsay Angus, Wim J.G. Oyen, Carla M.L. van Herpen, Thomas C. Kwee, Adrienne H. Brouwers, Eline Boon

Publikováno v: Verhoeff, S R, van Es, S C, Boon, E, van Helden, E, Angus, L, Elias, S G, Oosting, S F, Aarntzen, E H, Brouwers, A H, Kwee, T C, Heskamp, S, Hoekstra, O S, Verheul, H, van der Veldt, A A M, de Vries, E G E, Boerman, O C, van der Graaf, W T A, Oyen, W J G & van Herpen, C M L 2019, ' Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 9, pp. 1931-1939 . https://doi.org/10.1007/s00259-019-04358-9
European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1931-1939. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 46, 1931-1939
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1931. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1931-1939. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 46(9), 1931-1939. SPRINGER
European Journal of Nuclear Medicine and Molecular Imaging, 46, 9, pp. 1931-1939

Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18fa35968023bca2a3e9f115930859d3
https://dspace.library.uu.nl/handle/1874/389954

Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer

Autor: Suzanne C van Es, Elisabeth G.E. de Vries, Danielle J. Vugts, Erik J van Helden, Otto S. Hoekstra, G.A.M.S. (Guus) van Dongen, Derk Jan A. de Groot, Henk M.W. Verheul, Marc C. Huisman, Catharina Wilhelmina Menke, Eline Boon, Carla M.L. van Herpen

Publikováno v: Journal of Clinical Oncology. 35:e15117-e15117

e15117 Background: One third of patients with RAS wild-type metastatic colorectal cancer (mCRC) do not benefit from anti-EGFR inhibitors. Thus, predictive biomarkers to identify patients with primary resistant mCRC are urgently needed. Methods: Patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a59457eee0dbdb76706c8275e7ee965
https://doi.org/10.1200/jco.2017.35.15_suppl.e15117

Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic breast cancer (MBC)

Autor: Henk M.W. Verheul, Otto S. Hoekstra, Erik F. J. de Vries, Andor W. J. M. Glaudemans, Jim Janssen, Carl Moons, Winette van de Graaf, Lioe-Fee de Geus-Oei, Frederike Bensch, Liesbeth de Vries, Eline Boon, S.G. Elias, Erik J van Helden, Carolien P. Schröder, Adrienne H. Brouwers, Marc C. Huisman, Eric J. W. Visser, Willemien Menke-van der Hoeven van Oordt, Johan de Jong, Wim J.G. Oyen

Publikováno v: Cancer Research. 75:OT3-2

Background: Therapy of newly identified MBC is largely based on estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status. Optimal receptor information should be up-to-date and preferably from the whole body, given receptor co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40097e007fd998228e15ddb7832ae6a7
https://doi.org/10.1158/1538-7445.sabcs14-ot3-2-01